Fatigue is listed as a common adverse reaction in FDA prescribing information, occurring in 5% or more of patients taking Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide), with higher frequency than placebo in clinical trials
Retrieved from Sood, N., Garg, R
Cognitive variability in bipolar II disorder: who is cognitively impaired and who is preserved
FDA approval for a new indication for Wegovy (semaglutide) to reduce the risk of major adverse cardiovascular events, including cardiovascular death, heart attack, and stroke, in adults with cardiovascular disease and obesity or overweight
One good way to capitalize on it is to invest in pharmaceutical companies that currently lead this niche or have the potential to establish a strong foothold
Develop habits that minimize light exposure: return vials to storage immediately after access, work in reduced lighting when handling sensitive peptides, and use amber vials for light-sensitive compounds